Mobilization of peripheral blood stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in advanced gastric cancer

Oncology Reports

Volumn 12, Issue 2, 2004, Pages 323-332

  Ueda, Yuji ^a   Sonoda, Yoshiaki ^a   Fujiki, Hiroshi ^a   Harada, Sachio ^a   Kimura, Takafumi ^a   Itoh, Tsuyoshi ^a   Imura, Kenichiro ^a   Naito, K E I ^a   Nomura, Kenichi ^a   Taniwaki, Masafumi ^a   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cancer vaccine therapy; Dendritic cell; Gastric cancer; High dose chemotherapy; Peripheral blood stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; CELL SEPARATION; CYTOLOGY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; LYMPH NODE METASTASIS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; STEM CELL; STEM CELL MOBILIZATION; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DOXORUBICIN; ETOPOSIDE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUTROPHILS; STEM CELLS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 13844299960     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.2.323     Document Type: Article

References (42)

1. Preusser P, Wilke H, Achterrath W, et al: Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin. Anticancer Res 6: 1195-1196, 1986. (Pubitemid 17229573)
2. Preusser P and Wilke H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989. (Pubitemid 19220134)
3. Wilke H, Preusser P, Fink TJ, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7: 1318-1326, 1989. (Pubitemid 19220135)
4. Lerner A, Gonin R, Steele GD Jr and Mayer RJ: Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adeno-carcinoma: results of a phase II trial: J Clin Oncol 10: 536-540, 1992.
5. Taal BG, Huinink WWB, Franklin H and Rodenhuis S: EAP in advanced gastric cancer (letter to the editor). J Clin Oncol 8: 939-940, 1990. (Pubitemid 20148292)
6. Haim N, Tsalik M and Robinson E: Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules. Oncology 51: 102-107, 1994. (Pubitemid 24008650)
7. Schuhmacher CP, Fink U, Becker K, et al: Neoadjuvant therapy for patient with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918-927, 2001.
8. Kelsen D, Atiq OT, Saltz AL, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
9. Postmus PE, De Vries EGE, De Vries-Hospers HG, et al: Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation: a dose escalation study. Eur J Clin Oncol 20: 777-782, 1984. (Pubitemid 14107317)
10. Ajani JA, Roth JA, Ryan MB, et al: Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 11:22-28, 1993. (Pubitemid 23059970)
11. Suzuki T, Ochiai T, Nagata M, et al: High-dose chemotherapy with autologous bone marrow transplantation in the treatment of advanced gastric cancer. Cancer 72: 2537-2542, 1993. (Pubitemid 23320211)
12. Teshima T, Harada M, Takamatsu Y, et al: Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haematopoietic stem cells. Br J Haematol 84: 570-573, 1993. (Pubitemid 23248045)
13. Berdel WE, Heldmann T, Germer C, et al: Phase II pilot trial of preoperative high-dose chemotherapy in patients with malignant tumors of the upper gastrointestinal tract. Int J Oncol 9: 613-617, 1996. (Pubitemid 26316524)
14. Berdel WE, Heldmann T and Thiel E: Long-term results of a phase II pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract. Oncol Rep 8: 341-342, 2001. (Pubitemid 33758090)
15. Reichle A, Bolder U, Bataille F, et al: A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease. Bone Marrow Transplant 32: 665-671, 2003. (Pubitemid 37264907)
16. Lauren P: The two histological types of gastric carcinoma: an attempt to reach a histoclinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
17. Sonoda Y, Okuda T, Yokota S, et al: Activation of human interleukin-4/B-cell stimulation factor-1 on proliferation and differentiation of enriched hematopoietic progenitor cells in culture. Blood 75: 1615-1621, 1990. (Pubitemid 20145746)
18. Nukaya I, Yasumoto M, Iwasaki T, et al: Identification of HLA-A24 epitope peptide of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 80: 92-97, 1999. (Pubitemid 28559783)
19. Itoh T, Ueda Y, Kawashima I, et al: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 51: 99-106, 2002. (Pubitemid 34230724)
20. Ueda Y, Itoh T, Nukaya I, et al: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 24: 909-917, 2004.
21. Ajani JA, Baker J, Pisters PWT, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94: 641-646, 2002. (Pubitemid 34132291)
22. Ajani JA: Docetaxel for gastric and esophageal carcinomas. Oncology 16: S89-S96, 2002.
23. Preusser P and Wilke H: EAP in advanced gastric cancer (reply to the editor): J Clin Oncol 8: 940-941, 1990.
24. Schmitz N, Linch DC, Dreger P, et al: Randomized trial of filgrastim-mobilized peripheral progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353-357, 1996.
25. Storek J, Dawson MA, Storer B, et al: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97: 3380-3389, 2001.
26. Richman CM, Weiner RS and Yankee RA: Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031-1037, 1976.
27. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409, 1991.
28. To LB: Is our current strategy in manipulating hemopoiesis in autologous transplantation correct? Stem Cells 11: 283-287, 1993.
29. Kessinger A: High dose chemotherapy with autologous marrow transplantation for advanced gastrointestinal adenocarcinomas. Dig Dis 4: 203-207, 1986.
30. Santos GW: Overview of autologous bone marrow transplantation. Int J Cell Cloning 3: 215-216, 1985.
31. Neidhart JA, Kohler W, Stidley C, et al: Phase I study of repeated cycle of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 8: 1728-1738, 1990. (Pubitemid 20334329)
32. Bokemeyer C, Kollmannsberger C, Meisner A, et al: First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis first-line chemotherapy. J Clin Oncol 17: 3450-3456, 1999. (Pubitemid 29517914)
33. Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin- 4 and downregulated by tumor necrosis factor-alpha. J Exp Med 179: 1109-1115, 1994.
34. McIlroy D and Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52: 583-591, 2003. (Pubitemid 37268190)
35. Tarte K, Lu ZY, Fiol G, Legouffe E, Rossi JF and Klein B: Generation of virtually pure and potentially proliferating dendritic cells from patients with multiple myeloma. Blood 90: 3482-3495, 1997. (Pubitemid 27473418)
36. +cell- depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 4: 2709-2716, 1998.
37. Takamatsu Y, Akashi K, Harada M, et al: Cytokine production by peripheral blood monocytes and T cells during heamatopoietic recovery after intensive chemotherapy. Br J Haematol 83: 21-27, 1993. (Pubitemid 23030166)
38. Saito M, Kiyokawa N, Taguchi T, et al: Granulocyte colonystimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol 30: 1115-1123, 2002.
39. Lister J, Rybka WB, Donnenberg AD, et al: Autologous peripheral blood stem cell transplantation and adoptive immuno-therapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1: 607-614, 1995.
40. Fujii S, Shimizu K, Fujimoto K, et al: Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 90: 1117-1129, 1999.
41. Reichardt VL, Okada CY, Liso A, et al: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93:2411-2419,1999. (Pubitemid 29153646)
42. Itoh T, Ueda Y, Okugawa K, et al: Streptococcal preparation OK432 promotes functional maturation of human monocytederived dendritic cells. Cancer Immunol Immunother 52: 207-214, 2003. (Pubitemid 36535280)